Viatris Inc. VTRS

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
43/100
Developing

About Viatris Inc.

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It … Full VTRS analysis →

Competitive advantage assessment

Key strengths

  • Cash Generation Consistent Cash generation is consistent (score 0.76), indicating reliable business model.
  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.75), demonstrating pricing resilience across cycles.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.26), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.24), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
39

Where VTRS ranks in Drug Manufacturers - Specialty & Generic

Viatris Inc. ranks #43 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 47%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near VTRS in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
39 Cronos Group Inc. Common Share CRON 46/100 Developing
40 Tilray Brands, Inc. TLRY 45/100 Developing
41 Organigram Holdings Inc. OGI 45/100 Developing
42 Perrigo Company plc PRGO 43/100 Developing
43 Viatris Inc. VTRS 43/100 Developing
44 Intercure Ltd. INCR 42/100 Developing
45 TherapeuticsMD, Inc. TXMD 42/100 Developing
46 Aytu BioPharma, Inc. AYTU 42/100 Developing
47 Journey Medical Corporation DERM 41/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How VTRS scores on the Corporate Default defenses

Pricing Power

Score 39 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 56 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 62 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 39 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 35 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 29 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding VTRS's moat

What is Viatris Inc.'s moat score?

Viatris Inc. (VTRS) scores 43 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #43 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 47%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Customer Stickiness (62/100) and its weakest is Scale & Market Position (29/100).

How does Viatris Inc. compare with other Drug Manufacturers - Specialty & Generic companies?

Viatris Inc. ranks #43 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Perrigo Company plc (PRGO) at 43 just above it and Intercure Ltd. (INCR) at 42 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Viatris Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Viatris Inc.?

The Corporate Default template measures 6 defenses, and VTRS scores: Pricing Power (39), Cost Advantage (56), Customer Stickiness (62), Capital Efficiency (39), Resilience (35), Scale & Market Position (29). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000